[Federal Register Volume 76, Number 81 (Wednesday, April 27, 2011)]
[Notices]
[Pages 23627-23628]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-10144]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated October 6, 2010, and published in the Federal 
Register on October 14, 2010, 75 FR 63203, PCAS-Nanosyn, LLC, 3331-B 
Industrial Drive, Santa Rosa, California 95403, made application to the 
Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the following basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methamphetamine (1105).....................  II
Methylphenidate (1724).....................  II
Phencyclidine (7471).......................  II
Codeine (9050).............................  II
Diprenorphine (9058).......................  II
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Hydrocodone (9193).........................  II
Methadone (9250)...........................  II
Morphine (9300)............................  II
Oxymorphone (9652).........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------


    The company is a contract manufacturer. At the request of the 
company's customers, it manufactures derivatives of controlled 
substances in bulk form only. The primary service provided by the 
company to its customers is the development of the process of 
manufacturing the derivative. As part of its service to its customers, 
the company distributes the derivatives of the controlled substances it 
manufactures to those customers. The company's customers use the newly-
created processes and the manufactured derivatives in furtherance of 
formulation processes and dosage form manufacturing; pre-clinical 
studies, including toxicological studies; clinical studies supporting 
investigational Drug Applications; and use in stability studies.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
PCAS-Nanosyn, LLC to manufacture the listed basic classes of controlled 
substances is consistent with the public interest at this time. DEA has 
investigated PCAS-Nanosyn, LLC to ensure that the company's 
registration is consistent with the public interest. The investigation 
has included inspection and testing of the company's physical security 
systems, verification of the company's compliance with State and local 
laws, and a review of the company's background and history. Therefore, 
pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, 
the above named company is granted registration as a bulk manufacturer 
of

[[Page 23628]]

the basic classes of controlled substances listed.

    Dated: April 15, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2011-10144 Filed 4-26-11; 8:45 am]
BILLING CODE 4410-09-P